Services for COVID-19 Drug Repositioning

Access fast anti-COVID-19 drug discovery & repositioning strategies

Many drug discovery and drug repurposing strategies are currently being launched in the world to develop safe and effective COVID-19 treatments.

SARS-CoV Spike protein:ACE2 inhibitor in vitro screening assays

Our laboratories have recently developed 2 novel in vitro service assays to screen for potential drug inhibitors binding to SARS-CoV-2 Spike protein:ACE2 receptor.

ACE2:SARS-CoV-2 Spike Inhibitor Screening Assay Service

Designed for screening and profiling inhibitors of the ACE2:Spike interaction

The Spike RBD (B.1.1.7 Variant-UK variant) (N501Y)(SARS-CoV-2):ACE2 Inhibitor Screening

Designed for screening and profiling inhibitors of the interaction of ACE2 with the UK variant (N501Y) of the SARS-CoV-2 Spike RBD protein, both Colorimetric and Chemiluminescence methods are available

The Spike S1 RBD (B.1.351- South Africa variant) (SARS-CoV-2): ACE2 Inhibitor Screening

Designed for screening and profiling inhibitors of the interaction of ACE2 with the RBD region of the B.1.351 variant of the SARS-CoV-2 Spike S1 protein, both Colorimetric and Chemiluminescence methods are available

SARS-CoV-2 Spike:ACE2 Inhibitor Screening Assay Service
Designed for screening and profiling inhibitors of the Spike:ACE2 interaction

SARS-CoV-2 Spike/ACE2 Pseudovirus-based cell-based assays

Let our lab validate the SARS-CoV-2 Spike/ACE2 binding inhibitory effect of your selected compounds in a physiological context, with our newly developed Pseudovirus-based cell based assay.

COVID-19 related in vitro Enzyme Activity & Inhibitor Screening Assays

Activity Assays

Furin Activity Assay Kit (Fluorimetric)
DPP4 Activity Assay Kit (Fluorimetric)
ADAM 10 and ADAM 18 Activity Assay Kit (Fluorimetric)
JAK1 Activity Assay Kit (Fluorimetric)
Renin Activity Assay Kit (Fluorimetric)
SARS-CoV-2, 3CL Protease (Main/MPro) Activity Assay Testing

The 3CL protease, also known as Main Protease (Mpro), plays an important role in processing the polyproteins that are translated from the viral RNA. Potential 3CL Protease inhibitors that might block viral replication are therefore promising potential drug candidates to treat patients suffering with the COVID-19 coronavirus infection.

Our 3CL Protease Assay Services are designed to measure SARS-CoV-2 3CL Protease activity for screening and profiling applications.

The 3CL Protease inhibitor GC376 is used as a positive control to facilitate the identification and characterization of your potential 3CL protease inhibitors.